Redx is pleased to announce a cancer research collaboration with Horizon Discovery Group plc, (“Horizon”), the international life science group.
The collaboration will focus on Redx’s existing pan-RAF inhibitor program, which is focused on colorectal cancer, the fourth most common cancer and the second most common cause of cancer death in the UK.
Redx’s pan-RAF inhibitor program has identified next generation novel small molecule inhibitors of RAF kinases as potential treatments for colorectal and other potential cancers. These next generation pan-Raf inhibitors have been designed to overcome resistance mechanisms seen with first generation Raf inhibitors in colorectal cancer. As part of the collaboration, Horizon will deploy its proprietary gene editing, cell line and drug discovery technology platforms and know how to help explore the mode of action of Redx’s pan-RAF inhibitors and support the Company as it seeks to move this rare class of compounds towards licensing.
Under the terms of the agreement, Redx and Horizon will bear costs proportionately to respective research activities and have agreed a revenue share for any successful out-licensing.
Neil Murray, Chief Executive of Redx, commented: “Our pan-RAF inhibitor program is dealing with novel biology and is at a very interesting point. Our partnership with Horizon will enable us to detail at molecular level the effects of our pan-RAF inhibitors and help to progress this very promising program as we seek to secure a license partner for this asset.”
Dr Darrin M. Disley, Chief Executive Officer of Horizon, commented: “We are delighted to be able to support Redx with our proprietary technology platforms as they move towards securing a licensing agreement for these novel assets.”